OBJECTIVE: Spontaneous inflammatory responses initiated by NLRP3 mutations promote inflammasome-mediated interleukin-1β (IL-1β) processing and release and can induce rapid necrotic cell death. The cells that produce IL-1β in neonatal-onset multisystem inflammatory disease (NOMID) have not been clearly identified, nor have the mechanisms mediating IL-1β release and cell death been completely elucidated. METHODS: Whole blood cells were stimulated with lipopolysaccharide (LPS) in the presence of cathepsin B and caspase 1 inhibitors, followed by ATP treatment. Supernatants were collected and incubated with IL-1β-capturing beads. Cells were fixed, permeabilized, and stained for a combination of cell surface and intracellular markers, and a novel flow cytometry bead-based assay was used to measure secreted IL-1β. LPS-stimulated cells were also evaluated using immunofluorescence microscopy. RESULTS: Monocytes characterized by CD14(high) -CD16(low) expression and intracellular CD83 were increased in NOMID patients and were responsible for the majority of IL-1β production in response to LPS stimulation. This population of monocytes also underwent a rapid death response with LPS alone that is temporally associated with IL-1β and ASC release and has characteristic features of pyronecrotic but not pyroptotic cell death. Inhibition of cell death reduced IL-1β production from NOMID patient cells. In addition, IL-1 triggered cell death in monocytes from NOMID patients. CONCLUSION: Our findings indicate that monocytes are the predominant IL-1β-producing cell population in the peripheral blood of NOMID patients. Furthermore, they suggest that IL-1 receptor blockade may work in part by preventing pyronecrotic cell death, which may be an important target in NOMID and other forms of cryopyrin-associated periodic syndromes.
OBJECTIVE: Spontaneous inflammatory responses initiated by NLRP3 mutations promote inflammasome-mediated interleukin-1β (IL-1β) processing and release and can induce rapid necrotic cell death. The cells that produce IL-1β in neonatal-onset multisystem inflammatory disease (NOMID) have not been clearly identified, nor have the mechanisms mediating IL-1β release and cell death been completely elucidated. METHODS: Whole blood cells were stimulated with lipopolysaccharide (LPS) in the presence of cathepsin B and caspase 1 inhibitors, followed by ATP treatment. Supernatants were collected and incubated with IL-1β-capturing beads. Cells were fixed, permeabilized, and stained for a combination of cell surface and intracellular markers, and a novel flow cytometry bead-based assay was used to measure secreted IL-1β. LPS-stimulated cells were also evaluated using immunofluorescence microscopy. RESULTS: Monocytes characterized by CD14(high) -CD16(low) expression and intracellular CD83 were increased in NOMID patients and were responsible for the majority of IL-1β production in response to LPS stimulation. This population of monocytes also underwent a rapid death response with LPS alone that is temporally associated with IL-1β and ASC release and has characteristic features of pyronecrotic but not pyroptotic cell death. Inhibition of cell death reduced IL-1β production from NOMID patient cells. In addition, IL-1 triggered cell death in monocytes from NOMID patients. CONCLUSION: Our findings indicate that monocytes are the predominant IL-1β-producing cell population in the peripheral blood of NOMID patients. Furthermore, they suggest that IL-1 receptor blockade may work in part by preventing pyronecrotic cell death, which may be an important target in NOMID and other forms of cryopyrin-associated periodic syndromes.
Authors: Cailin H Sibley; Nikki Plass; Joseph Snow; Edythe A Wiggs; Carmen C Brewer; Kelly A King; Christopher Zalewski; H Jeffrey Kim; Rachel Bishop; Suvimol Hill; Scott M Paul; Patrick Kicker; Zachary Phillips; Joseph G Dolan; Brigitte Widemann; Nalini Jayaprakash; Frank Pucino; Deborah L Stone; Dawn Chapelle; Christopher Snyder; John A Butman; Robert Wesley; Raphaela Goldbach-Mansky Journal: Arthritis Rheum Date: 2012-07
Authors: Alberto Baroja-Mazo; Fatima Martín-Sánchez; Ana I Gomez; Carlos M Martínez; Joaquín Amores-Iniesta; Vincent Compan; Maria Barberà-Cremades; Jordi Yagüe; Estibaliz Ruiz-Ortiz; Jordi Antón; Segundo Buján; Isabelle Couillin; David Brough; Juan I Arostegui; Pablo Pelegrín Journal: Nat Immunol Date: 2014-06-22 Impact factor: 25.606
Authors: Jae Jin Chae; Young-Hun Cho; Geun-Shik Lee; Jun Cheng; P Paul Liu; Lionel Feigenbaum; Stephen I Katz; Daniel L Kastner Journal: Immunity Date: 2011-05-19 Impact factor: 31.745
Authors: Marcello F Stein; Stefan Lang; Thomas H Winkler; Andrea Deinzer; Sebastian Erber; Dirk M Nettelbeck; Elisabeth Naschberger; Ramona Jochmann; Michael Stürzl; Robert K Slany; Thomas Werner; Alexander Steinkasserer; Ilka Knippertz Journal: Mol Cell Biol Date: 2013-01-22 Impact factor: 4.272
Authors: Marco Gattorno; Sara Tassi; Sonia Carta; Laura Delfino; Francesca Ferlito; Maria Antonietta Pelagatti; Andrea D'Osualdo; Antonella Buoncompagni; Maria Giannina Alpigiani; Maria Alessio; Alberto Martini; Anna Rubartelli Journal: Arthritis Rheum Date: 2007-09
Authors: Hal M Hoffman; Martin L Throne; N J Amar; Mohamed Sebai; Alan J Kivitz; Arthur Kavanaugh; Steven P Weinstein; Pavel Belomestnov; George D Yancopoulos; Neil Stahl; Scott J Mellis Journal: Arthritis Rheum Date: 2008-08
Authors: Davide Ferrari; Cinzia Pizzirani; Elena Adinolfi; Roberto M Lemoli; Antonio Curti; Marco Idzko; Elisabeth Panther; Francesco Di Virgilio Journal: J Immunol Date: 2006-04-01 Impact factor: 5.422